Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 326 clinical trials
None
Eosinophilic Cationic Protein as a Biomarker in Diagnosis of Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Chronic obstructive pulmonary disease. Eosinophilic Cationic Protein has various biological activities, including antibacterial, antiviral, antiparasitic and neurotoxic functions, and it contributes to

respiratory symptom
bronchodilator
acute exacerbation of chronic obstructive pulmonary disease
forced expiratory volume
spirometry
  • 0 views
  • 02 May, 2021
  • 1 location
None
TDF Combined With LDT for the Treatment of HBeAg-positive Hepatitis B Patients With Poor Response to TDF for 12 Months

> Telbivudine has a strong antiviral effect.Studies have shown that the HBeAg seroconversion rate of HBeAg positive CHB for one year was 25%, which was higher than other nucleosides, and it could also improve

  • 0 views
  • 03 Feb, 2021
  • 1 location
None
LDT Combined With TDF to Improve EGFR Decreasing in Patients With Chronic Hepatitis B Treated With TDF

effect has reached a relatively ideal effect, but its therapeutic effect still has great room for improvement. Tenofovir(TDF) is the first-line antiviral treatment with good clinical efficacy

  • 0 views
  • 27 Jan, 2021
  • 1 location
None
Prediction of BKvirus Nephropathy Risk by the NEPHROVIR Method in Kidney Transplant Patients With BKvirus Viremia

in more than 50% of cases. Without current antiviral therapy, the treatment consists of minimizing immunosuppression, secondarily exposing the patient to a graft rejection risk. Impaired BKv specific

immunosuppression
kidney transplant
immunosuppressants
renal impairment
  • 0 views
  • 03 Oct, 2021
  • 1 location
None
Study of Oral Glecaprevir/Pibrentasvir Tablets in Participants Aged 12 Years or Older With Chronic Hepatitis C to Assess Sustained Virological Response

infection will be enrolled. This is a prospective (conducted in future) study in therapy of direct-acting antiviral (DAA) treatment-experienced participants with chronic hepatitis C genotype 1. Around 67

  • 0 views
  • 05 Dec, 2021
  • 5 locations
None
Future Destinations: Journeys Towards Citizenship

" literature describes the transformative experience of HCV cure and how people took steps towards a "normal life" moving beyond substance use. Recent advances in Direct-Acting Antiviral (DAA) medicines

liver disease
hepatitis c antibody
antiviral drugs
cancer
substance use
  • 0 views
  • 01 May, 2021
  • 1 location
None
REal-Life Cohort With DOlutegravir + LAmivudina

last decade new drugs have improved tolerance and posology of these treatment. However PLHIV needs to continue the treatment and will likely remain on antiviral therapy for many years. In the recent

  • 0 views
  • 14 Apr, 2021
  • 1 location
None
Latent HIV-1 Viral Suppress and Hope for HIV Cure

suppressed HIV infected men and women, who will be prospectively followed to document antiviral cocktail, viral suppression and incidences of rebound, measure the size of the latent HIV reservoir and examine

  • 0 views
  • 26 Jul, 2021
  • 1 location
None
Monitoring the IgG/IgM Antibodies in COVID-19 Patients

repurposed and employed, but no specific antiviral medicine has been approved by the FDA to treat this disease. Although three vaccines have been approved by the FDA, mutations in the SARS-CoV-2 may cause

  • 0 views
  • 16 Jul, 2021
  • 2 locations
None
Predictive Immune Biomarkers of COVID-19 Pathogenesis to Influence Therapeutic Management

deterioration often coincides with the development of host antiviral immune responses. The inflammatory response to SARS-CoV-2 infection may underpin COVID-19 pathogenesis leading to aberrant and excessive

  • 0 views
  • 26 Jan, 2021
  • 2 locations